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Abstract This paper describes the development of
the ISBT 128 coding and labeling for cellular therapy
products. It is published on behalf of the international
Cellular Therapy Coding and Labeling Advisory
Group (see www.ICCBBA.org)
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Abbreviations
AABB American Association of Blood Banks
ASBMT American Society for Blood and Marrow
Transplantation
ASFA American Society for Apheresis
APBMT Asia Paciﬁc Blood and Marrow
Transplantation Group
CT Cellular Therapy
CTCLAG Cellular Therapy Coding and Labeling
Advisory Group
EBMT The European group for Blood and
Marrow Transplantation
EU European Union
ISCT International Society for Cellular
Therapy
FACT Foundation for the Accreditation of
Cellular Therapy
FDA Food and Drug Administration
JACIE Joint Accreditation Committee of ISCT
and EBMT
NMDP National Marrow Donor Program
WHO World Health Organization
WMDA World Marrow Donor Association
Introduction
ISBT 128 is a coding and labeling system which was
developed for blood and blood products to improve
quality, safety and traceability in blood banking by the
International Society of Blood Transfusion (ISBT). It
was launched at the meeting of the ISBT in Amster-
dam in 1994 and since then, the system has been
integrated inblood banks all over the world.Today the
standard is managed by ICCBBA.
Cellular therapy (CT) started with stem cell trans-
plantation using bone marrow as a source of hemato-
poietic progenitor cells (HPC, bone marrow) in the
early 1980s. This ﬁeld has been rapidly expanding in
the last two decades, because other sources like
mobilised progenitor cells harvested by apheresis
machines (HPC, Apheresis) and HPC from cord blood
(HPC, Cord Blood) have proved to be excellent
sources of HPCs for stem cell transplantation. Since
then, the treatment of patients with matched unrelated
donor transplants has improved considerably and now
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evident. The World Marrow Donor Association
(WMDA) published their data on export and import,
showing that nearly 50% of the HPC products for
matcheduntreateddonortransplantationareexchanged
internationally (WMDA 2008).
This exchange caused an urgent need within the
Regulatory Agencies worldwide and in Europe in
particular to develop an uniﬁed regulatory framework
to ensure high standards of quality and safety of
tissues and cells. This led to the publication of the
European Directive 2004/23/EC in 2004, entitled:
‘Setting standards on quality and safety for the
donation, procurement, testing, processing, preserva-
tion, storage and distribution of tissues and cells’.
In this EU-Directive the following issues for
coding and labeling were addressed:
• Ensurance of data protection and conﬁdentiality
• Assurance of traceability of tissues and cells
through laboratory identiﬁcation procedures,
record maintenance and an appropriate labelling
system
• Design of a single European coding system
At that time the emerging role of coding and
labeling of CT products to support worldwide
exchange was recognized by ICCBBA. Following the
EBMT-meeting in Prague in 2005, the ICCBBA
executive director arranged a meeting with technical
experts and representatives of the major organisations
in the ﬁeld: International Society for Cellular Therapy
(ISCT), the European group for Blood and Marrow
Transplantation (EBMT), and the accreditation organ-
isationsforstemcelltransplantcenters:theFoundation
for the Accreditation of Cellular Therapy (FACT) in
the USA and the Joint Accreditation Committee of
ISCT and EBMT (JACIE) in Europe. It was discussed
and decided to use ISBT 128 for all ‘‘cellular therapy’’
products to provide an uniform coding and labeling
system worldwide. This system provides:
• a globally unique donation identiﬁcation number
• international product description list with deﬁni-
tions and codes
• standard data structures for donation numbers,
product descriptions and other information for CT
products
This decision was then brought before the members
of the ISCT at the ISCT meeting in Vancouver in 2005
and was fully supported by the leadership of the
organisations involved and their members. To accom-
plish the work in the ﬁeld of CT, a Cellular Therapy
CodingandLabelingAdvisoryGroup(CTCLAG)was
launched.Theﬁrstface-to-facemeetingwasorganized
inAthensin2005.Thedecisionmakingmeetingonthe
new terminology and labeling was held in October
2006 at the headquarters of the American Association
of Blood Banks (AABB) in Bethesda, USA.
To date most of the worldwide operating organisa-
tions in CT support the group and sent representatives
to face-to-face meetings and on the teleconferences.
Participants in the group include AABB, Asia Paciﬁc
Blood and Marrow Transplantation (APBMT), Amer-
ican Society for Blood and Marrow Transplantation
(ASBMT), American Society for Apheresis (ASFA),
EBMT, FACT, FACT-Netcord, ISCT, ISCT-Europe,
JACIE, National Marrow Donor Program (NMDP),
WMDA and observers from the Food and Drug
Administration (FDA).
The activities of the CTCLAG
Since the start of the CTCLAG in 2005 its role has
been deﬁned as follows:
• review existing regulation regarding labeling;
• design CT product speciﬁc label templates that
satisfy regulatory requirements;
• provide a focus for the standardization of termi-
nology and product naming;
• promote the adoption of the ISBT 128 standard in
cellular therapy facilities around the world;
• provide advice and support to facilities introduc-
ing the standard;
• advise on the ongoing development of the ISBT
128 standard to support new developments in
cellular therapy.
In 2007, the group published two papers on CT
products simultaneously in Transfusion, Bone Mar-
row Transplantation and the Journal for Clinical
Apheresis, one paper on CT terminology and labeling
(Ashford et al. 2007a, b, c) and the related paper on
the implementation plan for cellular therapy products
(Ashford et al. 2007d, e, f).
As foreseen, terminology has more recently been
extended towards the newer CT-products like Ther-
apeutic Cells, Mesenchymal Stromal Cells (TC-MSC)
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for advanced therapy medicinal products (Regulation
(EC) no 1394/2007). The intention of this regulation
was to unify the regulatory framework for medical
devices, tissue engineering and medicinal products
including cellular and gene therapeutic products. This
initiative was required due to the regulatory gap for
tissue-engineered products as well as the rather broad
spectrum of legal and regulatory implementation in
the different EU member states.
In the meantime the European Commission (DG
Sanco) established a working group to establish
guidelines and to make speciﬁc recommendations on
the single European coding system. An international
CEN/ISSS workshop was held in Brussels from
November 2007–April 2008 in which the CTCLAG
and ICCBBA actively participated.
Although other Member States had set up national
coding systems, it was recognized that ISBT 128
fulﬁlls all requirements for the globally unique
donation code and provides international product
codes, which are being maintained by professionals
in the CTCLAG.
The Regulatory Committee of the EU however,
decided that an impact assessment was necessary and
so far no major decisions in Europe have been made.
In 2008, the accreditation bodies JACIE, FACT and
AABB published versions of their standards in which
ISBT 128 terminology became mandatory. Currently
theorganisationsareworkingonthenewversionoftheir
standards, in which it is foreseen that the transition to
ISBT128codingandlabelingwillbegraduallymoving
forward,ﬁrstly byrequiringanimplementationplanfor
ISBT 128 for CT products, followed by a later
requirement for full implementation.
In Summary
During the 5 years since the inception of the CTC-
LAG, a great deal of progress has been made. At the
end of 2009, 205 Facility identiﬁcation numbers
(FIN) assigned to Cellular Therapy Facilities in 37
countries (see Fig. 1). In the year 2009, 25 new CT
facilities registered with ICCBBA. The CT-terminol-
ogy has been updated by adding new classes and
product codes.
Organisations involved in Cellular Therapy world-
wide are participating in the CTCLAG
1 including
representation from regulatory bodies like the US
FDA. The next step for CTCLAG will be to
cooperate with WHO. The 63rd World Health
Assembly on May 21, 2010 discussed the situation
regarding human organ and tissue transplantation.
WHO was requested ‘‘to provide, in response to
requests from MS, technical support and regulation
on, and suitable and traceable coding systems for,
donation and transplantation of human cells, tissue or
organs, in particular by facilitating international
cooperation’’.
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1 ICCBA cellular therapy home page: http://www.iccbba.org/
cellulartherapy_home.html
Fig. 1 Registered CT-facilities with ICCBBA (2009)
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